Thanos Loukas, Ptohis Nikolaos, Pomoni Anastasia, Sotiropoulou Evangelia, Pomoni Maria, Kelekis Dimitrios
Department of Computed Tomography and Interventional Radiology, "Sotiria" General Hospital of Chest Diseases, Mesogion Avenue 152, 11527 Athens, Greece.
Case Rep Med. 2010;2010:151846. doi: 10.1155/2010/151846. Epub 2011 Jan 2.
The case of a 72-year-old male patient with HCC is presented in whom percutaneous RFA was used as the sole first-line anticancer treatment, since he denied having partial hepatectomy. The patient underwent RFA two more times, at 1.5 years for treating a local tumor progression at the initial ablation site and at 11 years after the first session for treating a new remote intrahepatic recurrence. He revealed a long-term survival of more than 12 years so far and still remains in excellent clinical status.
本文介绍了一名72岁的肝癌男性患者的病例,该患者因拒绝接受部分肝切除术,将经皮射频消融术(RFA)作为唯一的一线抗癌治疗方法。该患者又接受了两次RFA治疗,一次是在1.5年后,用于治疗初始消融部位的局部肿瘤进展;另一次是在首次治疗后的11年,用于治疗新出现的肝内远处复发。到目前为止,他已长期存活超过12年,且临床状况仍然良好。